• Je něco špatně v tomto záznamu ?

More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma

T. Jelinek, R. Bezdekova, D. Zihala, T. Sevcikova, A. Anilkumar Sithara, L. Pospisilova, S. Sevcikova, P. Polackova, M. Stork, Z. Knechtova, O. Venglar, V. Kapustova, T. Popkova, L. Muronova, Z. Chyra, M. Hrdinka, M. Simicek, JJ. Garcés, N. Puig,...

. 2023 ; 41 (7) : 1383-1392. [pub] 20221031

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004045

Grantová podpora
C355/A26819 Cancer Research UK - United Kingdom

PURPOSE: Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ≥ 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels. METHODS: We assessed the levels of CTCs by multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM to establish a cutoff for CTCs that identifies the patients with ultra-high-risk PCL-like MM. We tested the cutoff on 185 transplant-eligible patients with MM and further validated on an independent cohort of 280 transplant-ineligible patients treated in the GEM-CLARIDEX trial. The largest published real-world cohort of patients with primary PCL was used for comparison of survival. Finally, we challenged the current 5% threshold for primary PCL diagnosis. RESULTS: Newly diagnosed transplant-ineligible patients with MM with 2%-20% CTCs had significantly shorter progression-free survival (3.1 v 15.6 months; P < .001) and overall survival (14.6 v 33.6 months; P = .023) than patients with < 2%. The 2% cutoff proved to be applicable also in transplant-eligible patients with MM and was successfully validated on an independent cohort of patients from the GEM-CLARIDEX trial. Most importantly, patients with 2%-20% CTCs had comparable dismal outcomes with primary PCL. Moreover, after revealing a low mean difference between flow cytometric and morphologic evaluation of CTCs, we showed that patients with 2%-5% CTCs have similar outcomes as those with 5%-20% CTCs. CONCLUSION: Our study uncovers that ≥ 2% CTCs is a biomarker of hidden primary PCL and supports the assessment of CTCs by flow cytometry during the diagnostic workup of MM.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004045
003      
CZ-PrNML
005      
20230425141046.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.22.01226 $2 doi
035    __
$a (PubMed)36315921
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jelinek, Tomas $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000254679253
245    10
$a More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma / $c T. Jelinek, R. Bezdekova, D. Zihala, T. Sevcikova, A. Anilkumar Sithara, L. Pospisilova, S. Sevcikova, P. Polackova, M. Stork, Z. Knechtova, O. Venglar, V. Kapustova, T. Popkova, L. Muronova, Z. Chyra, M. Hrdinka, M. Simicek, JJ. Garcés, N. Puig, MT. Cedena, A. Jurczyszyn, JJ. Castillo, M. Penka, J. Radocha, MV. Mateos, JF. San-Miguel, B. Paiva, L. Pour, L. Rihova, R. Hajek
520    9_
$a PURPOSE: Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ≥ 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels. METHODS: We assessed the levels of CTCs by multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM to establish a cutoff for CTCs that identifies the patients with ultra-high-risk PCL-like MM. We tested the cutoff on 185 transplant-eligible patients with MM and further validated on an independent cohort of 280 transplant-ineligible patients treated in the GEM-CLARIDEX trial. The largest published real-world cohort of patients with primary PCL was used for comparison of survival. Finally, we challenged the current 5% threshold for primary PCL diagnosis. RESULTS: Newly diagnosed transplant-ineligible patients with MM with 2%-20% CTCs had significantly shorter progression-free survival (3.1 v 15.6 months; P < .001) and overall survival (14.6 v 33.6 months; P = .023) than patients with < 2%. The 2% cutoff proved to be applicable also in transplant-eligible patients with MM and was successfully validated on an independent cohort of patients from the GEM-CLARIDEX trial. Most importantly, patients with 2%-20% CTCs had comparable dismal outcomes with primary PCL. Moreover, after revealing a low mean difference between flow cytometric and morphologic evaluation of CTCs, we showed that patients with 2%-5% CTCs have similar outcomes as those with 5%-20% CTCs. CONCLUSION: Our study uncovers that ≥ 2% CTCs is a biomarker of hidden primary PCL and supports the assessment of CTCs by flow cytometry during the diagnostic workup of MM.
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x farmakoterapie $7 D009101
650    12
$a plazmocelulární leukemie $7 D007952
650    _2
$a prognóza $7 D011379
650    _2
$a plazmatické buňky $x patologie $7 D010950
650    12
$a nádorové cirkulující buňky $x patologie $7 D009360
650    _2
$a nádorové biomarkery $7 D014408
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bezdekova, Renata $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000184270750
700    1_
$a Zihala, David $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000345850773
700    1_
$a Sevcikova, Tereza $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000287040106 $7 xx0247813
700    1_
$a Anilkumar Sithara, Anjana $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000325406966
700    1_
$a Pospisilova, Lenka $u Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic
700    1_
$a Sevcikova, Sabina $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Polackova, Petra $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Stork, Martin $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Czech Republic
700    1_
$a Knechtova, Zdenka $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Czech Republic
700    1_
$a Venglar, Ondrej $u Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000206199861
700    1_
$a Kapustova, Veronika $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000299375667
700    1_
$a Popkova, Tereza $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000158854218
700    1_
$a Muronova, Ludmila $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Chyra, Zuzana $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000348072532
700    1_
$a Hrdinka, Matous $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000229812825
700    1_
$a Simicek, Michal $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000323882723 $7 xx0247832
700    1_
$a Garcés, Juan-Jose $u Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain $1 https://orcid.org/0000000192354671
700    1_
$a Puig, Noemi $u Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233, Salamanca, Spain $1 https://orcid.org/0000000175353861
700    1_
$a Cedena, Maria-Teresa $u Hospital 12 de Octubre, CIBER-ONC number CB16/12/00369, Madrid, Spain $1 https://orcid.org/0000000158513720
700    1_
$a Jurczyszyn, Artur $u Plasma Cell Dyscrasia Center, Department of Hematology, Jagiellonian University Medical College, Faculty of Medicine Cracow, Poland
700    1_
$a Castillo, Jorge J $u Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA $1 https://orcid.org/0000000194907532
700    1_
$a Penka, Miroslav $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Radocha, Jakub $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000253848238 $7 xx0233189
700    1_
$a Mateos, Maria Victoria $u Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16/12/00233, Salamanca, Spain $1 https://orcid.org/0000000323901218
700    1_
$a San-Miguel, Jesús F $u Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain $1 https://orcid.org/0000000291834857 $7 xx0060803
700    1_
$a Paiva, Bruno $u Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain $1 https://orcid.org/0000000319773815
700    1_
$a Pour, Ludek $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000262747009
700    1_
$a Rihova, Lucie $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000336398463
700    1_
$a Hajek, Roman $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000169556267 $7 nlk20000083645
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 41, č. 7 (2023), s. 1383-1392
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36315921 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141043 $b ABA008
999    __
$a ok $b bmc $g 1924607 $s 1190254
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 41 $c 7 $d 1383-1392 $e 20221031 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
GRA    __
$a C355/A26819 $p Cancer Research UK $2 United Kingdom
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace